BG61625B1 - Определяне съдържанието на синдекан в биологични материаликато тъкани и телесни течности за установяване на злокачественитрансформации на клетки - Google Patents

Определяне съдържанието на синдекан в биологични материаликато тъкани и телесни течности за установяване на злокачественитрансформации на клетки Download PDF

Info

Publication number
BG61625B1
BG61625B1 BG97950A BG9795093A BG61625B1 BG 61625 B1 BG61625 B1 BG 61625B1 BG 97950 A BG97950 A BG 97950A BG 9795093 A BG9795093 A BG 9795093A BG 61625 B1 BG61625 B1 BG 61625B1
Authority
BG
Bulgaria
Prior art keywords
syndecan
sample
cells
content
malignant
Prior art date
Application number
BG97950A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG97950A (bg
Inventor
Markku T. Jalkanen
Markku S. Mali
Pirjo L. Inki
Jarkko Kirjavainen
Sirpa M. Leppae
Original Assignee
Markku T. Jalkanen
Markku S. Mali
Pirjo L. Inki
Jarkko Kirjavainen
Sirpa M. Leppae
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27093707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG61625(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Markku T. Jalkanen, Markku S. Mali, Pirjo L. Inki, Jarkko Kirjavainen, Sirpa M. Leppae filed Critical Markku T. Jalkanen
Publication of BG97950A publication Critical patent/BG97950A/bg
Publication of BG61625B1 publication Critical patent/BG61625B1/bg

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BG97950A 1991-01-15 1993-07-15 Определяне съдържанието на синдекан в биологични материаликато тъкани и телесни течности за установяване на злокачественитрансформации на клетки BG61625B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64120991A 1991-01-15 1991-01-15
US72133091A 1991-07-01 1991-07-01
PCT/FI1991/000399 WO1992013274A1 (en) 1991-01-15 1991-12-19 Detection of syndecan content in biological materials such as tissues and body fluids for indications of malignant transformations of cells

Publications (2)

Publication Number Publication Date
BG97950A BG97950A (bg) 1995-02-28
BG61625B1 true BG61625B1 (bg) 1998-01-30

Family

ID=27093707

Family Applications (1)

Application Number Title Priority Date Filing Date
BG97950A BG61625B1 (bg) 1991-01-15 1993-07-15 Определяне съдържанието на синдекан в биологични материаликато тъкани и телесни течности за установяване на злокачественитрансформации на клетки

Country Status (23)

Country Link
US (1) US5422243A (ru)
EP (2) EP0569367B1 (ru)
JP (1) JP3103377B2 (ru)
KR (1) KR0162670B1 (ru)
AT (1) ATE166157T1 (ru)
AU (1) AU650936B2 (ru)
BG (1) BG61625B1 (ru)
CA (1) CA2100077C (ru)
CZ (1) CZ282203B6 (ru)
DE (1) DE69129417T2 (ru)
DK (1) DK0569367T3 (ru)
ES (1) ES2116331T3 (ru)
FI (1) FI104347B1 (ru)
HU (1) HU215778B (ru)
IE (2) IE920107A1 (ru)
NO (1) NO314604B1 (ru)
NZ (1) NZ241273A (ru)
PL (1) PL168188B1 (ru)
PT (1) PT100008B (ru)
RU (1) RU2139540C1 (ru)
SK (1) SK281583B6 (ru)
WO (1) WO1992013274A1 (ru)
ZA (1) ZA92271B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726058A (en) * 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
EP0671909B1 (en) * 1992-12-01 2000-12-27 Oy Biotie Therapies Syndecan stimulation of cellular differentiation
US6017727A (en) * 1994-03-07 2000-01-25 Biotie Therapies Ltd. Syndecan enhancer element and syndecan stimulation of cellular differentiation
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
GB9519490D0 (en) * 1995-09-25 1995-11-29 Melvin William T Use of a cytochrome P450 enzyme in tumour cells as a marker and target
US6385546B1 (en) 1996-11-15 2002-05-07 Rutgers, The University Of New Jersey Stabilizing and destabilizing proteins
CZ299874B6 (cs) * 1997-08-12 2008-12-17 Leadd B. V. Zpusob urcení transformacní schopnosti cinidel, zpusob urcení predispozice bunky, zpusob zjištení genové mutace, použití nukleové kyseliny kódující apoptin a diagnostická testovací souprava
EP1146903A4 (en) * 1998-10-16 2005-02-16 Univ California GLYPICANE FOR THE DETECTION AND TREATMENT OF HUMAN CARCINOMA
US6998232B1 (en) * 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
WO2001077682A1 (fr) * 2000-04-10 2001-10-18 Institut Bioorganicheskoi Khimii Imeni Akademikov M.M. Shemyakina I Ju. A. Ovchinnikova Rossiisskoi Akademii Nauk Anticorps diriges contre le facteur hldf, procedes de fabrication correspondants, peptides avec des capacites antigeniques et a hydrolyse hk et procede de diagnostic de l'etat anaplasique de cellules humaines
WO2002086084A2 (en) * 2001-04-04 2002-10-31 Quark Biotech, Inc. Sequence characteristics of bladder cancer
KR100694804B1 (ko) * 2005-05-18 2007-03-14 아주대학교산학협력단 작은 헤어핀 ｒｎａ 분자를 포함하는 자궁 내막암 치료또는 예방용 조성물 및 그를 이용한 자궁 내막암 치료 또는예방 방법
US8347890B2 (en) * 2006-06-19 2013-01-08 Insono Therapeutics, Inc. Automated tissue retention system
US20090220588A1 (en) * 2008-02-21 2009-09-03 Massachusetts Institute Of Technology Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity
GB0803272D0 (en) * 2008-02-22 2008-04-02 Smith & Nephew Ultrasound and tissue repair

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3511199A1 (de) * 1985-03-28 1986-10-02 Hoechst Ag, 6230 Frankfurt Verfahren zur immunologischen bestimmung von heparansulfat-proteoglykan, verfahren zur herstellung bzw. reinigung von dafuer geeignetem heparansulfat-proteoglykan aus basalmembran-haltigen geweben
US4859581A (en) * 1986-03-10 1989-08-22 Board Of Regents, The University Of Texas System Endoglycosidase assay
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
JPH02156898A (ja) * 1988-12-08 1990-06-15 Seikagaku Kogyo Co Ltd 抗低密度型ヘパラン硫酸プロテオグリカンモノクローン抗体、それを産生するハイブリドーマおよびこのモノクローン抗体を用いる低密度型ヘパラン硫酸プロテオグリカンの検出方法
WO1990007712A1 (de) * 1988-12-23 1990-07-12 Bissendorf Peptide Gmbh Antigen, assoziiert mit degenerativen erscheinungen des zentralen nervensystems (zns), dagegen gerichtete antikörper sowie verfahren zur diagnose von dysfunktionen des zns
WO1990012033A1 (en) * 1989-03-29 1990-10-18 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
WO1993005167A1 (en) * 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses

Also Published As

Publication number Publication date
PT100008B (pt) 1999-06-30
FI104347B (fi) 1999-12-31
ZA92271B (en) 1992-10-28
DE69129417T2 (de) 1998-11-05
FI933211A0 (fi) 1993-07-15
HU9302030D0 (en) 1993-11-29
HU215778B (hu) 1999-02-01
JPH06504616A (ja) 1994-05-26
CA2100077A1 (en) 1992-07-16
IE990011A1 (en) 2000-11-01
EP0569367B1 (en) 1998-05-13
US5422243A (en) 1995-06-06
ES2116331T3 (es) 1998-07-16
FI933211A (fi) 1993-09-15
RU2139540C1 (ru) 1999-10-10
PT100008A (pt) 1993-02-26
PL168188B1 (pl) 1996-01-31
AU9071391A (en) 1992-08-27
ATE166157T1 (de) 1998-05-15
HUT67587A (en) 1995-04-28
EP0816851A3 (en) 2000-08-23
AU650936B2 (en) 1994-07-07
DE69129417D1 (de) 1998-06-18
DK0569367T3 (da) 1998-10-07
CZ282203B6 (cs) 1997-05-14
IE920107A1 (en) 1992-07-15
WO1992013274A1 (en) 1992-08-06
EP0569367A1 (en) 1993-11-18
JP3103377B2 (ja) 2000-10-30
FI104347B1 (fi) 1999-12-31
NO314604B1 (no) 2003-04-14
EP0816851A2 (en) 1998-01-07
SK281583B6 (sk) 2001-05-10
NZ241273A (en) 1993-10-26
CZ137293A3 (en) 1994-01-19
BG97950A (bg) 1995-02-28
CA2100077C (en) 1999-11-16
KR0162670B1 (ko) 1999-05-01
SK73893A3 (en) 1993-11-10
NO932552L (no) 1993-07-14
NO932552D0 (no) 1993-07-14

Similar Documents

Publication Publication Date Title
Hanamura et al. Expression of fibronectin and tenascin‐C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas
Gillenwater et al. Expression of galectins in head and neck squamous cell carcinoma
BG61625B1 (bg) Определяне съдържанието на синдекан в биологични материаликато тъкани и телесни течности за установяване на злокачественитрансформации на клетки
JP2007516693A (ja) 癌の治療および診断のための組成物および方法
Berndt et al. Evidence of ED-B+ fibronectin synthesis in human tissues by non-radioactive RNA in situ hybridization. Investigations on carcinoma (oral squamous cell and breast carcinoma), chronic inflammation (rheumatoid synovitis) and fibromatosis (Morbus Dupuytren)
Mahesparan et al. Extracellular matrix-induced cell migration from glioblastoma biopsy specimens in vitro
Haglund et al. Expression of laminin in pancreatic neoplasms and in chronic pancreatitis
Dippel et al. Expression of the c‐kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo
Menon et al. A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin.
Antinheimo et al. Proliferative potential of sporadic and neurofibromatosis 2-associated schwannomas as studied by MIB-1 (Ki-67) and PCNA labeling
Kosmehl et al. Differential expression of fibronectin splice variants, oncofetal glycosylated fibronectin and laminin isoforms in nodular palmar fibromatosis
JP4868152B2 (ja) 癌細胞の悪性度判定法
US20080267955A1 (en) Frizzled 9 as tumor marker
US7807790B2 (en) Peptide sequence that promotes tumor invasion
Ito et al. Expression of cell adhesion molecule 1 in malignant pleural mesothelioma as a cause of efficient adhesion and growth on mesothelium
JP2800850B2 (ja) 新生物形成の検出方法
Izadifar et al. Expression of transforming growth factor β1 and its receptors in normal human urothelium and human transitional cell carcinomas
JP2007532889A (ja) 癌の進行度をモニタリングする方法
Charpin et al. ELAM selectin expression in breast carcinomas detected by automated and quantitative immunohistochemical assays.
US20040235073A1 (en) Kruppel-like transcriptional factor KLF4/GKLF and uses thereof
Charpin et al. VLA2 integrin expression in breast carcinomas evaluated by automated and quantitative immunohistochemistry
CA2452094A1 (en) Screening method for identifying cancer therapy-relevant compounds
WOLF et al. Oral Communication: Neuro/Endocrinopathology
Mahesparan et al. Received: 8 June 1998/Revised: 13 August 1998/Accepted: 17 August 1998